Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 10, 2022Critical Reviews in Oncology/HematologyOpen Access

Development of asciminib, a novel allosteric inhibitor of BCR-ABL1

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDelphine RéaInstitut BergoniéTHTimothy P. HughesSouth Australia Pathology

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Réa et al. (2022) studied this question.

synapsesocial.com/papers/6a16d7e52fcf950e00055ae3https://doi.org/10.1016/j.critrevonc.2022.103580
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias1988 · 863 citations
  2. 2Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia2014 · 126 citations
  3. 3Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy2018 · 379 citations